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Abstract
A nine-year-old male black Giant Schnauzer dog was referred
for the scintigraphic evaluation with a history of malignant fibrosar-
coma with a rapidly growing non painful mass on the left shoulder
region quite near to the site of an operation performed four months
ago. We carried out oncological scintigraphy using pentavalent
99mTechnetium labelled dimercaptosuccinic acid [99mTc(V)-
-DMSA], a tumour localising radiopharmaceutical agent. The study
was performed to assess the margins, vascularity of the tumour
and response to the cancer therapy. Uniform intense radiophar-
maceutical uptake was observed in the lesion indicating its mar-
gins, vascularity and malignant nature. The dog was subjected to
external radiation therapy to control the growth of the cancer and
to bring the tumour mass to an operable size. The dog was fol-
lowed up with 99mTc(V)-DMSA scintigraphy pre-irradiation and
post-irradiation. Immediately after the post-irradiation scintigra-
phy, the dog was operated on. During the surgery, resection of
the tumour margins was performed carefully using
a hand held gamma probe to assure that no tumour tissue was
left inside. In conclusion, the authors would like to state that
99mTc(V)-DMSA oncoscintigraphy is valuable in the assessment
and evaluation of therapy in canine soft tissue cancer.
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Introduction
Cancer incidence in dogs is quite high; mainly in the form of
osteosarcoma, breast carcinoma and other soft tissue tumours
like fibrosarcoma and mastocytoma. Cancer detection and its
management is an important aspect in animal cancers. Scintigra-
phy has been in routine use for the detection and management of
a variety of cancers in human beings. Scintigraphy for animal can-
cer management is uncommon and very few centres are involved
in this work.
99mTc(V)-DMSA is a diagnostic radiopharmaceutical agent
for soft tissue cancer. It has been reported with good efficacy in
diagnosis of primary site, its size and metastatic lesions in soft
tissue tumours in humans [1, 3, 10]. Papantoniou et al. have shown
that DMSA scintimammography has an advantage and could im-
prove the detection of non-palpable in situ breast carcinomas [9].
Similarly, Kiratli et al. and Wang et al. found applicability with good
detection sensitivity of 99mTc(V)-DMSA for hepatocellular carci-
noma and retinoblastoma respectively [6, 11]. Ohta et al. repor-
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ted that 99mTc(V)-DMSA could demarcate the lesion well and was
useful in following up recurrent extra abdominal fibromatosis [8].
There are several reports regarding the sensitivity of 99mTc(V)-
-DMSA scintigraphy in medullary thyroid carcinoma [7]. Hirano et
al. suggests the clinical utility of 99mTc(V)-DMSA in imaging pri-
mary brain tumours and differentiating their histological malignancy
grade non-invasively [4] . Kobayashi et al. found that low-grade
malignant and highly recurrent benign lesions, which often recur
after surgery, were detected more accurately with 99mTc(V)-DMSA
Scintigraphy than with 67Ga-citrate scintigraphy [5]. There are only
a few reports about 99mTc(V)-DMSA scintigraphy in dogs for the
diagnosis of soft tissue cancer [2]. In the present study, the au-
thors used 99mTc(V)-DMSA imaging for assessment of the res-
ponse of fibrosarcoma to external radiation therapy.
Case report
A nine-year-old male black Schnauzer dog was referred for
scintigraphic evaluation with a history of a large, growing, hard
mass in the right shoulder region at the site of an operation per-
formed four months ago. The general condition of the dog was
very good with no history of pain, lameness or weight loss. At the
time of examination, the mass felt hard and homogeneous. The
dog showed no signs of pain upon palpation and otherwise there
were no abnormal findings.
Scintigraphy
Scintigraphy was performed using Penta-DMSA@ [99mTc(V)-
-DMSA] obtained from Medi-Radiopharma Ltd, Budapest, Hun-
gary. 99mTechnetium pertechnatate was eluted from dry gel gen-
erator and labelling was done according to the prescribed proto-
col. 450 Mbq of the radiopharmaceutical was injected intravenou-
sly. Imaging studies were performed under general anaesthesia.
Static images of the tumour mass were acquired at three hours
post injection of 99mTc(V)-DMSA. The study was performed at
a different time period during the cancer management and the
scans are shown in Figures 1 A, B and C. These scans were ac-
quired in a dorsoventral position with 300 k counts using a large
field of view single head digital SPECT (single photon emission
computed tomography) gamma camera (Nucline X-ring, Mediso
Ltd., Budapest, Hungary) with LEGP (low energy general purpose)
collimator. Image processing of all images was done using Inter-
viewfi  software. The scintigraphy was performed three times:
Figure 1. 99mTc(V)-DMSA scintigraphy A. Pre RT B. Post RT; C. Post operation.
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pre-irradiation, post-irradiation just before surgery and two weeks
later. Pre-surgery scintigraphy was utilized for careful resection of
the tumour margins using a hand held gamma probe to assure
that no tumour tissue was left inside. The region of interest was
drawn on the primary tumour and on the shoulder region pre and
post irradiation, to compare the change in size in terms of re-
sponse to the radiation therapy. It was found that pre irradiation
the ROI size, on the basis of radiopharmaceutical uptake, was
14702 mm† and post irradiation it was measured at 1888 mm†.
External radiation therapy
Radiation therapy was performed using a 60Co-irradiator
(Gammatron, Siemens, Germany), three times a week for two
weeks with 12 Gy exposure. The total dose delivered was 72 Gy.
The radiation therapy was given in dorsoventral position keeping
the tumour mass exactly under the beam while the rest of the area
was protected using lead shielding to prevent radiation exposure
to the left lobe of the lung. The whole procedure was performed
under anaesthesia.
Discussion
The role of 99mTc(V)-DMSA is well known in the diagnosis of
primary soft tissue malignancies. In the present case, scintographic
procedure provided valuable information about the size, vascu-
larity and nature of the tumour mass. In this study, the usefulness
of scintigraphy is shown in the follow-up and treatment evaluation
in cancer therapy in animals. There was a significant reduction in
tumour mass on the basis of tumour uptake using region of inter-
est (ROI) quantification. The dog was operated on after radiation
therapy. The oncoscintigraphy was performed before operation
and the residual tumour tissue was detected using a hand-held
gamma probe and removed very efficiently. No apparent recur-
rence was present in the following six months. Besides 99mTc(V)-
-DMSA scintigraphy can also be used for mapping tumour mar-
gins and then replacing the diagnostic radionuclide with a thera-
peutic one for radionuclide therapy. For this purpose, Rhenium is
a beta energy emitting radionuclide suitable for radioisotope ther-
apy with the added advantage of having a similar chemistry to
Technetium. Therefore 99mTc(V)-DMSA distribution quantitative-
ly predicts 188Re(V)-DMSA  distribution, and hence can be easily
used as a diagnostic agent followed by radionuclide therapy. In
conclusion we would like to state that diagnostic scintigraphy us-
ing 99mTc(V)-DMSA gives information about tumour functionality
non-invasively which is useful in understanding the treatment re-
sponse and disease process. This information is of value for the
management of soft tissue cancer in animals.
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